PH12022550003A1 - Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions - Google Patents
Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensionsInfo
- Publication number
- PH12022550003A1 PH12022550003A1 PH1/2022/550003A PH12022550003A PH12022550003A1 PH 12022550003 A1 PH12022550003 A1 PH 12022550003A1 PH 12022550003 A PH12022550003 A PH 12022550003A PH 12022550003 A1 PH12022550003 A1 PH 12022550003A1
- Authority
- PH
- Philippines
- Prior art keywords
- fluticasone propionate
- preparation
- ophthalmic aqueous
- nanosuspensions
- nanocrystals
- Prior art date
Links
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002159 nanocrystal Substances 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title 1
- 239000006070 nanosuspension Substances 0.000 abstract 3
- 208000010217 blepharitis Diseases 0.000 abstract 2
- 210000000744 eyelid Anatomy 0.000 abstract 2
- 230000000699 topical effect Effects 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010015943 Eye inflammation Diseases 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 210000000720 eyelash Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877599P | 2019-07-23 | 2019-07-23 | |
| US201962942551P | 2019-12-02 | 2019-12-02 | |
| PCT/IB2020/056832 WO2021014348A1 (en) | 2019-07-23 | 2020-07-21 | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550003A1 true PH12022550003A1 (en) | 2022-11-14 |
Family
ID=71738074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550003A PH12022550003A1 (en) | 2019-07-23 | 2020-07-21 | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11406596B2 (enExample) |
| EP (1) | EP3769753B1 (enExample) |
| JP (2) | JP7021301B2 (enExample) |
| KR (1) | KR20220038443A (enExample) |
| CN (2) | CN115120557B (enExample) |
| AU (1) | AU2020317084A1 (enExample) |
| CA (1) | CA3145055A1 (enExample) |
| CY (1) | CY1124930T1 (enExample) |
| DK (1) | DK3769753T3 (enExample) |
| ES (1) | ES2905793T3 (enExample) |
| HR (1) | HRP20220165T1 (enExample) |
| HU (1) | HUE057416T2 (enExample) |
| LT (1) | LT3769753T (enExample) |
| MD (1) | MD3769753T2 (enExample) |
| MX (1) | MX420447B (enExample) |
| PH (1) | PH12022550003A1 (enExample) |
| PL (1) | PL3769753T3 (enExample) |
| PT (1) | PT3769753T (enExample) |
| RS (1) | RS62932B1 (enExample) |
| SI (1) | SI3769753T1 (enExample) |
| SM (1) | SMT202200082T1 (enExample) |
| TW (1) | TWI864053B (enExample) |
| WO (1) | WO2021014348A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020317084A1 (en) * | 2019-07-23 | 2022-03-03 | Nicox Ophthalmics, Inc. | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
| CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
| CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0639070T4 (da) | 1992-05-06 | 2010-12-13 | Alcon Lab Inc | Anvendelse af borat-polyolkomplekser til ophtalmiske præparater |
| JP3450805B2 (ja) * | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | 水性医薬組成物 |
| US6900184B2 (en) * | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
| US20060229219A1 (en) | 2005-04-11 | 2006-10-12 | Advanced Medical Optics, Inc. | Borate-polyol mixtures as a buffering system |
| US8010032B2 (en) * | 2005-05-23 | 2011-08-30 | Xerox Corporation | Fuser member comprising deflocculated material |
| WO2010141834A1 (en) | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
| TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸－多元醇錯合物之水性藥學組成物 |
| US20130065888A1 (en) | 2011-08-15 | 2013-03-14 | Biserka Cetina-Cizmek | Ophthalmic formulations and processes for their preparation |
| DK3517541T3 (da) | 2012-05-08 | 2020-09-07 | Nicox Ophthalmics Inc | Polymorf form af fluticasonpropionat |
| CA2893654A1 (en) * | 2012-12-17 | 2014-06-26 | Glaxo Group Limited | Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions |
| TWI773641B (zh) | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑 |
| AU2020317084A1 (en) * | 2019-07-23 | 2022-03-03 | Nicox Ophthalmics, Inc. | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
-
2020
- 2020-07-21 AU AU2020317084A patent/AU2020317084A1/en not_active Abandoned
- 2020-07-21 US US16/934,807 patent/US11406596B2/en active Active
- 2020-07-21 LT LTEP20186965.8T patent/LT3769753T/lt unknown
- 2020-07-21 PH PH1/2022/550003A patent/PH12022550003A1/en unknown
- 2020-07-21 TW TW109124497A patent/TWI864053B/zh active
- 2020-07-21 HR HRP20220165TT patent/HRP20220165T1/hr unknown
- 2020-07-21 KR KR1020227006020A patent/KR20220038443A/ko active Pending
- 2020-07-21 CN CN202210807241.1A patent/CN115120557B/zh active Active
- 2020-07-21 SM SM20220082T patent/SMT202200082T1/it unknown
- 2020-07-21 MD MDE20210297T patent/MD3769753T2/ro unknown
- 2020-07-21 DK DK20186965.8T patent/DK3769753T3/da active
- 2020-07-21 US US17/629,267 patent/US20220241296A1/en not_active Abandoned
- 2020-07-21 EP EP20186965.8A patent/EP3769753B1/en active Active
- 2020-07-21 JP JP2020124238A patent/JP7021301B2/ja active Active
- 2020-07-21 RS RS20220142A patent/RS62932B1/sr unknown
- 2020-07-21 CN CN202010707466.0A patent/CN111821261B/zh active Active
- 2020-07-21 HU HUE20186965A patent/HUE057416T2/hu unknown
- 2020-07-21 PT PT201869658T patent/PT3769753T/pt unknown
- 2020-07-21 SI SI202030032T patent/SI3769753T1/sl unknown
- 2020-07-21 ES ES20186965T patent/ES2905793T3/es active Active
- 2020-07-21 CA CA3145055A patent/CA3145055A1/en active Pending
- 2020-07-21 WO PCT/IB2020/056832 patent/WO2021014348A1/en not_active Ceased
- 2020-07-21 PL PL20186965T patent/PL3769753T3/pl unknown
- 2020-07-21 MX MX2022000928A patent/MX420447B/es unknown
-
2022
- 2022-01-27 CY CY20221100069T patent/CY1124930T1/el unknown
- 2022-02-03 JP JP2022015508A patent/JP7494230B2/ja active Active
- 2022-06-27 US US17/850,515 patent/US20220323352A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| PH12022550003A1 (en) | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions | |
| PH12015502587A1 (en) | Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
| EA201790889A1 (ru) | Офтальмологический раствор | |
| WO2018033792A3 (en) | Ophthalmic pharmaceutical compositions and uses relating thereto | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| MX2020009132A (es) | Composiciones farmaceuticas que comprenden nebivolol. | |
| EP4279063A3 (en) | Ophthalmic pharmaceutical composition, preparation method therefor and application thereof | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| MX2016006256A (es) | Tratamiento de glaucoma usando laquinimod. | |
| WO2015094019A3 (ru) | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости | |
| MX391659B (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular | |
| MX2019011242A (es) | Farmacos y composiciones para el tratamiento de trastornos oculares. | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| HK1219654A1 (zh) | 用於治疗眼科疾病和病症的方法 | |
| BR112022001202A2 (pt) | Processo para a preparação de propionato aquoso de fluticasona estéril na form a suspensões de nanocristas | |
| MX2023012758A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis. | |
| MA53146B1 (fr) | Procédé de préparation de suspensions aqueuses ophtalmiques stériles de nanocristaux de forme a de propionate de fluticasone | |
| EP4365299A3 (en) | Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal disease | |
| MX2020006429A (es) | Agente terapeutico para el glaucoma que comprende un agonista de fp y un bloqueador beta. |